logo

For the Inventor, By the Inventor

Newton, MA, United States of America

Karyopharm Therapeutics Inc.

Calculating rank
USPTO Granted Patents = 44

% Expired Patents = 2.3



Forward Citations = 574

Loading Chart...
Loading Chart...

22 inventors (with patents filed for the assignee):

goldMedal Sharon Shacham (30 out of 51 patents)

silverMedal Sharon Shechter (28 out of 37 patents)

bronzeMedal Dilara McCauley (27 out of 44 patents)

4.  Erkan Baloglu (21 out of 36 patents)

5.  Vincent Premaratna Sandanayaka (17 out of 41 patents)

6.  William Senapedis (13 out of 13 patents)

7.  Ori Kalid (11 out of 13 patents)

8.  Yosef Landesman (11 out of 11 patents)

9.  Gali Golan (11 out of 11 patents)

10.  Brian C Austad (8 out of 32 patents)

11.  David Gregory Roe (8 out of 28 patents)

12.  Trinayan Kashyap (5 out of 5 patents)

13.  Michael Kauffman (3 out of 3 patents)

14.  Stephen Edmund Gottschling (2 out of 4 patents)

15.  Tami Rashal (1 out of 1 patent)


Core Competencies:
Nuclear Transport Modulators
Selinexor
XPO1 Inhibitors
Polymorphs
Hydrazide Compounds
Cancer Treatment
Co-crystal Forms
Multicyclic Compounds
Heteroaryl Derivatives
Triazolyl Acrylamides
Wound Healing
Substituted Compounds

44 patents:

1. 12766188 - Uses of IL-12 as a replacement immunotherapeutic (2026-10-20),
2. 12709609 - CRYSTALLINE FORM OF SELINEXOR (2026-08-18),
3. 12673939 - Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms (2026-07-07),
4. 12577225 - Nuclear transport modulators and uses thereof (2026-03-17),
5. 12559478 - Co-crystal forms of selinexor (2026-02-24),
6. 12479806 - Process for preparing XPO1 inhibitors and intermediates for use in the preparation of XPO1 inhibitors (2025-11-25),
7. 12371420 - Polymorphs of Selinexor (2025-07-29),
8. 12331040 - Substituted benzofuranyl and benzoxazolyl compounds and uses thereof (2025-06-17),
9. 12318386 - Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer (2025-06-03),
10. 12291508 - Hydrazide containing nuclear transport modulators and uses thereof (2025-05-06),
11. 11945794 - Nuclear transport modulators and uses thereof (2024-04-02),
12. 11807629 - Polymorphs of Selinexor (2023-11-07),
13. 11787771 - Hydrazide containing nuclear transport modulators and uses thereof (2023-10-17),
14. 11753401 - Polymorphs of Selinexor (2023-09-12),
15. 11746102 - Polymorphs of selinexor (2023-09-05),
Company Overview
Karyopharm Therapeutics Inc. is a biopharmaceutical company based in Newton, Massachusetts, focused on the development of innovative therapies for the treatment of cancer and other serious diseases. The company specializes in the discovery and commercialization of novel drugs that target the nuclear transport system, a critical pathway in cellular function. Karyopharm's research efforts are centered on advancing its proprietary SINE (Selective Inhibitor of Nuclear Export) technology, aiming to improve patient outcomes through targeted therapies.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Karyopharm Therapeutics Inc. USPTO Patent Assignee Logo
44 Patents

#5 in Newton, MA

#456 in Massachusetts

#7,960 in US

#15,768 in the World

Newton, MA (US)
Newton, MA, United States of America

Karyopharm Therapeutics Inc.

Forward Citations = 574

22 inventors:

goldMedal Sharon Shacham (30 out of 51 patents)

silverMedal Sharon Shechter (28 out of 37 patents)

bronzeMedal Dilara McCauley (27 out of 44 patents)

4.  Erkan Baloglu (21 out of 36 patents)

5.  Vincent Premaratna Sandanayaka (17 out of 41 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Karyopharm Therapeutics Inc.. Retrieved from https://idiyas.com/company/karyopharm-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…